MPL - NPM
Unknown
30 enrolled
Oral Adherence in Hematological Oncology Agents and Impact on Comorbid Therapy Adherence
Phase NA Unknown
30 enrolled
Study of Blood and Bone Marrow Samples in Patients With Chronic Myelogenous Leukemia Enrolled on a CALGB Clinical Trial
Unknown
60 enrolled
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
Phase 1 Unknown
10 enrolled
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Phase 1/2 Unknown
100 enrolled
Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)
Unknown
191 enrolled
Symptom Burden in Chronic Myeloid Leukemia (CML)
Unknown
210 enrolled
ToTem
Phase 1 Unknown
18 enrolled
Consolidation Treatment With Ponatinib 15 mg on Treatment Free-Remission Rate in Patients With Chronic Myeloid Leukemia
Phase 2 Unknown
40 enrolled
ProT4
Phase 2 Unknown
114 enrolled
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
Phase 2 Unknown
25 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
Phase NA Unknown
35 enrolled
Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Phase 3 Unknown
800 enrolled
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
1,000 enrolled
Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome
Phase 2 Unknown
25 enrolled
Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation
Phase 1/2 Unknown
25 enrolled
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
Phase 3 Unknown
400 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia
Phase 1/2 Unknown
60 enrolled
Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
Phase 3 Unknown
Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease
Phase NA Unknown
200 enrolled
Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant
Unknown
125 enrolled
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Phase 3 Unknown
750 enrolled
Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients
Unknown
60 enrolled
AML-14A
Phase 1/2 Unknown
114 enrolled
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
Phase 2 Unknown
66 enrolled
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
Phase 2 Unknown
Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Phase 3 Unknown
80 enrolled
Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome
Phase 3 Unknown
220 enrolled
AlloTreo
Phase 2 Unknown
175 enrolled
Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants
Unknown
200 enrolled
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Phase 2 Unknown
54 enrolled
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
Phase 3 Unknown
207 enrolled
Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Phase 2 Unknown
40 enrolled